Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AquaVita NextGen vs TeleCareSpot

By GLP-1 ScorecardUpdated

AquaVita NextGen
Site position #465

Lower grade

TeleCareSpot
Site position #178

Higher grade

Score comparison

TeleCareSpot has the higher recorded score — 67.7/100 to 56.3/100.

TeleCareSpot grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. TeleCareSpot lists compounded semaglutide at $299 per month across doses and tirzepatide at $399 per month. A separate consultation fee is credited toward medication if approved; confirm the medication and consultation charges before paying.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueTeleCareSpot +20
23
43
Dose & formulationTeleCareSpot +8
75
83
Clinical oversightTeleCareSpot +1
82
83
Labs & monitoringAquaVita NextGen +1
53
52
FulfillmentTeleCareSpot +30
62
92
Contract termsTeleCareSpot +14
47
61
AquaVita NextGen · top barTeleCareSpot · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricAquaVita NextGenTeleCareSpot
WeighScore56.3/10067.7/100
GradeCC
Site position#465#178
Semaglutide$375/mo (first-month rate, compounded)$299/mo (all doses, compounded; separate consultation fee credited toward medication if approved)
Tirzepatide$320/mo (starting dose, 3-month plan, compounded)$399/mo
Coverage5 states48 states
Brand-name accessNot confirmedNot confirmed
Oral / sublingualYesYes
AquaVita NextGen

Site position #465 · C

Strengths

  • Physical address in Lake Forest CA
  • Named medical director (Dr. Steve Groke)
  • Both semaglutide and tirzepatide including ODT tablets
  • Compounding disclaimer present on site

What to consider

  • Only 5 states (AZ, CA, FL, TX, NV)
  • LegitScript or PCAB accreditation has not been independently verified
  • Primarily a local medspa expanding into telehealth
  • Only a first-month semaglutide price ($375, originally $499) is published; ongoing monthly price and all tirzepatide pricing remain unpublished
TeleCareSpot

Site position #178 · C

Strengths

  • Listed medication prices are visible before intake: compounded semaglutide $299/month across doses and tirzepatide $399/month; the consultation fee is credited toward medication if approved
  • HIPAA compliance and licensed US physicians
  • Multiple options: compounded semaglutide, tirzepatide, oral tirzepatide, and phentermine
  • DNA-calibrated dosing option that tailors the GLP-1 dose to how you metabolize it
  • Broad coverage in 47 states and DC, with free shipping and cancel-anytime plans

What to consider

  • The LegitScript seal ID this provider publishes, #45936855, does not resolve on LegitScript's own CDN — checked August 2026, alongside six seal IDs from other providers that returned normally in the same pass
  • Compounded medications are not FDA-approved — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Not available in Alaska, Mississippi, or New Jersey
  • The compounding pharmacy partner is not named
  • A separate weight-loss consultation fee applies (credited toward your medication package if approved)
  • Trustpilot rating and review counts (4.9, 14,000+) are self-stated on the site

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard